

CMS Policy (L39365) CUSTOMER FAQ—July 7, 2023

- **Why is this FAQ necessary?**
 - CMS recently published a decision (L39365) that eliminated coverage for numerous molecular diagnostic tests, including PancaGEN®
- **Has CMS Policy (L39365) gone into effect?**
 - No. On July 6, 2023, Novitas Solutions, Inc. issued a statement that advised that the policy (L39365) will **not** become effective on July 17, 2023, the date originally stated within the new policy
- **How does this revised decision for CMS Policy (L39365) impact the availability of PancaGEN®?**
 - As a result of this revised decision, Interpace Diagnostics® is able to continue offering PancaGEN and the related Point2® fluid chemistry tests for amylase, CEA, and glucose without interruption
- **Is there a contact at Interpace that can provide more details regarding this situation?**
 - For more information, customers can contact the Interpace Client Services team by calling (800) 495-9885 or emailing clientservices@interpace.com
- **Can I still voice my support for PancaGEN with Novitas Solutions, Inc. and my concerns with the original CMS Policy, Genetic Testing for Oncology LCD (L39365)?**
 - Yes. Correspondence can be sent directly to the address below:

Patrick Mann, MD
Contractor Medical Director
A/B MAC JH and JL
Novitas Solutions, Inc.
2020 Technology Parkway, Suite 3001
Mechanicsburg, PA 17050